The delegation is made up of Vizzotti, the presidential adviser Cecilia Nicolini and technicians from the National Administration of Drugs, Food and Medical Technology (Anmat).
Vizzotti and Nicolini have already traveled to Russia in the October to learn more about the vaccine.
Then, the president Alberto Fernández announced through the Russian news agency Sputnik, in an exclusive interview, that the Government would acquire 10 million dose of Sputnik V .
Last Wednesday, the President signed a contract with the Russian Direct Investment Fund (RDIF) to immunize ten million people between January and February, with a first consignment of 300,000 antidotes that will arrive before the end of the year.
"We are going to be able to have enough doses to vaccinate ten million Argentines between January and February", said Fernández on that occasion.
Sputnik V had an efficacy greater than 95% at 21 days of the second dose in the prevention of coronavirus infection, according to preliminary results of its phase 3 studies.
Meanwhile, the Anmat reported yesterday in a statement that "officials of this agency will travel to the Federation Russian in order to visit the plants of the Gamaleya Institute, developer of the Sputnik V vaccine, and Generium, which is part of its production process. "
It is a vaccine that uses a platform (or technology) called "non-replicating vectors". Vectors are viruses that are genetically modified so that they do not have the capacity to reproduce in the body (and therefore harmless) and are used to transport genetic material of the virus to be immunized.
In this case, Sputnik V uses human adenovirus as vector and, unlike other candidates, it uses two adenoviruses (one different in each dose) to elicit a greater and more durable response in the immune system.
On August 11, Sputnik V was registered by the Ministry of Health of Russia and in September the vaccine was administered for the first time to a group of volunteers from the "red zones" of the hospitals of that country.
On September 4, the journal The Lancet published a research article Over the results of phase I and phase II clinical trials of the vaccine that did not show serious adverse events and an effective immune response of those vaccinated.
Meanwhile, on November 24, the Gamaleya Center and the RDIF (Russian Investment Fund) announced the positive results of the second interim data analysis of phase 3, double-blind, randomized, placebo-controlled clinical trials, which showed an efficacy of 91.4% seven days after the second dose and above 95% at 21 days after the second dose when volunteers formed a stable immune response.